This article has been updated to reflect comment from Cassava. Cassava Sciences (NASDAQ:SAVA) has plummeted more than 40% after a Maryland grand jury indicted a company paid consultant and researcher ...

As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Facing charges from the Securities and Exchange Commission for misleading claims ...

Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the Alzheimer’s disease world is being exposed and will hopefully get cleaned up. Remi Barbier, Cassava’s longtime CEO, has ...

Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel New Position Is Expected to Be Critical to Operations and Strategic Initiatives “Chris is an accomplished legal advisor, a ...

News is the latest setback for the clinical-stage biotech, which was the subject of SEC and Justice Department investigations earlier this year Cassava Sciences Inc.'s stock tumbled 85% Monday to put ...

・Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. ・The company added that it no longer expects to initiate the trial in question in the ...

Cassava says failed trial results have impacted its second Phase 3 trial, ReFocus-ALZ; decides to discontinue ReFocus-ALZ Cassava says it will continue to review the data and evaluate the next steps.

Cassava Sciences (NASDAQ: SAVA) ended the week with a piece of dispiriting news. It's going to reach deep into its coffers to settle charges brought by the most important financial-markets regulator ...

New Cassava executive chairman Rick Barry wrote an open letter to stakeholders. Barry acknowledged skepticism but stressed the potential for its Alzheimer's disease candidate simufilam. Cassava ...

The appointment of Dr. Jack Moore as Senior Vice President, Clinical Development brings extensive experience in CNS drug development, which could enhance the company’s initiatives for simufilam and ...

Shares of Cassava Sciences (NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, ...